Φαρμακευτικο Μαρκετινγκ: Θεωρια, Πρακτικη, Δεοντολογια

The ultimate guide for Pharma Marketing Champions

Ζητήστε το στα κεντρικά βιβλιοπωλεία ή δώστε την παραγγελία σας τώρα…

http://www.stamoulis.gr/ViewShopProduct.aspx?ProductId=402023

Durex: Έρευνα για τις παγκόσμιες συνήθειες στο σεξ

Η έρευνα διενεργήθηκε με στόχο την κατανόηση της οπτικής του ευρύ κοινού γύρω από την σεξουαλική ευεξία. Εγινε κατ’ εντολή της Durex, τη Νο1 εταιρεία προφυλακτικών στο κόσμο, η οποία υλοποιεί μια ευρεία γκάμα επικοινωνιακών ενεργειών υγείας προκειμένου να ενθαρρύνει το ασφαλέστερο και καλύτερο σεξ.

Σύμφωνα με τα ευρήματα της έρευνας τρεις στους τέσσερις ανθρώπους παγκοσμίως κάνουν σεξ τουλάχιστον μία φορά την εβδομάδα.

Boehringer Ingelheim launches beta social game Syrum to promote science and innovation

Boehringer Ingelheim has announced the beta launch of its first social game on Facebook, called Syrum. Syrum will be a new and evolving platform for the research-driven pharmaceutical company to inspire and educate in a changing digital world. In development for more than two years, Syrum has been specifically designed to demonstrate the complex processes around medicine research and development through gaming mechanics. It aims at promoting science and innovation to the digital community in a fun and engaging way.

Cialis Tablets Recommended for Approval for the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia in the EU

Eli Lilly and Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of Cialis® (tadalafil) tablets 5 mg for once a day use for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). The CHMP's opinion is now referred to the European Commission, which has the authority to approve medicines for the European Union (EU). The Commission usually issues a decision within one to two months following the CHMP opinion.

Mylan Launches First Generic Version of Diovan HCT® Tablets

Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Valsartan and Hydrochlorothiazide Tablets USP, 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg. This product is the generic version of Novartis' Diovan HCT^® Tablets, which are indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled with monotherapy or as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.(1)

Pharma creates non-profit R&D organisation

Ten biopharma companies have formed TransCelerate BioPharma Inc, a not-for-profit organisation using money and personnel from each firm, with a mission to speed up the development of new medicines.

The firms involved are: Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche’s Genentech and Sanofi.

The cost of R&D and a move away from blockbusters towards personalised medicines has seen manufacturers seek new models for finding and developing drugs in recent years.